



Correction to: Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer

Ai Amioka¹ · Takayuki Kadoya¹ · Satoshi Sueoka¹ · Yoshie Kobayashi¹ · Shinsuke Sasada¹ · Akiko Emi¹ · Norio Masumoto¹ · Masaaki Ito¹ · Koh Nakayama² · Morihito Okada¹

Published online: 28 June 2021
© The Japanese Breast Cancer Society 2021

Correction to: Breast Cancer
<https://doi.org/10.1007/s12282-021-01241-0>

In the original publication of the article, the first sentence in the heading “Conclusions” in “Abstract” section should be changed as “In ER-positive breast cancer, Wnt5a upregulates the CYP metabolic pathway and decrease the sensitivity to tamoxifen, paclitaxel, and cyclophosphamide, all of the three, standard treatment methods for ER-positive breast cancer.”

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s12282-021-01241-0>.

✉ Takayuki Kadoya
takayukikadoya@gmail.com

¹ Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima 734-8551, Japan

² Oxygen Biology Laboratory, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8510, Japan